Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) insider Janeen Noel Doyle sold 4,059 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total value of $56,947.77. Following the transaction, the insider directly owned 75,941 shares in the company, valued at approximately $1,065,452.23. This represents a 5.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Janux Therapeutics Trading Up 1.3%
Shares of JANX opened at $13.76 on Friday. Janux Therapeutics, Inc. has a twelve month low of $12.12 and a twelve month high of $35.34. The stock’s 50 day moving average is $14.51 and its two-hundred day moving average is $15.58. The firm has a market capitalization of $839.08 million, a PE ratio of -7.48 and a beta of 2.53.
Janux Therapeutics (NASDAQ:JANX – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.13. The business had revenue of $3.73 million during the quarter, compared to analysts’ expectations of $4.36 million. On average, sell-side analysts predict that Janux Therapeutics, Inc. will post -1.7 EPS for the current year.
Institutional Investors Weigh In On Janux Therapeutics
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the company. Truist Financial raised Janux Therapeutics to a “strong-buy” rating in a report on Monday, May 4th. Barclays lowered Janux Therapeutics from an “overweight” rating to an “underweight” rating and lowered their price objective for the company from $29.00 to $14.00 in a report on Monday, April 20th. JonesTrading lowered their price objective on Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, April 28th. Wall Street Zen raised Janux Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, April 5th. Finally, UBS Group lowered Janux Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $57.00 to $15.00 in a report on Wednesday, April 15th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $45.85.
View Our Latest Research Report on JANX
About Janux Therapeutics
Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.
Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.
Read More
- Five stocks we like better than Janux Therapeutics
- Macy’s Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious
- NVIDIA Sends a Message With RTX Spark—This Is What It Says
- Buy the Dip? Broadcom’s AI Moat Is Wider Than Ever
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
